IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.729
AS - Asia 2.010
EU - Europa 1.827
SA - Sud America 222
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.807
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.703
SG - Singapore 1.200
UA - Ucraina 830
CN - Cina 418
DE - Germania 301
FI - Finlandia 278
HK - Hong Kong 219
BR - Brasile 200
RU - Federazione Russa 151
IE - Irlanda 117
KR - Corea 86
SE - Svezia 56
IT - Italia 50
TR - Turchia 43
GB - Regno Unito 21
CA - Canada 15
AR - Argentina 12
EU - Europa 9
BD - Bangladesh 7
MX - Messico 7
AT - Austria 6
IN - India 5
MA - Marocco 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
VN - Vietnam 4
ES - Italia 3
FR - Francia 3
OM - Oman 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
IQ - Iraq 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
PK - Pakistan 2
PL - Polonia 2
SA - Arabia Saudita 2
VE - Venezuela 2
AM - Armenia 1
BH - Bahrain 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
JO - Giordania 1
LV - Lettonia 1
MK - Macedonia 1
NL - Olanda 1
NP - Nepal 1
RO - Romania 1
SN - Senegal 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 9.807
Salva come PNG Salva come JPEG
Città #
Fairfield 934
Jacksonville 632
Woodbridge 438
Singapore 404
Ashburn 371
Wilmington 369
Seattle 341
Cambridge 329
Houston 313
Chandler 306
Dearborn 284
Beijing 236
Hong Kong 219
Boardman 140
Princeton 134
Dublin 116
Ann Arbor 115
Seoul 85
San Diego 78
Hefei 71
Izmir 40
Norwalk 32
Ogden 29
Udine 26
Santa Clara 25
Kunming 22
São Paulo 19
New York 14
Los Angeles 12
Nanjing 12
Des Moines 10
Ottawa 10
Nanchang 9
Jinan 7
Belo Horizonte 6
Chengdu 6
Grafing 6
Guangzhou 6
Rio de Janeiro 6
Turku 5
Baku 4
Brasília 4
Brooklyn 4
Curitiba 4
Helsinki 4
Juiz de Fora 4
Toronto 4
Vienna 4
Atlanta 3
Campinas 3
Changsha 3
Chicago 3
Düsseldorf 3
Fuzhou 3
Genova 3
Hebei 3
Ho Chi Minh City 3
João Pessoa 3
Mexico City 3
Porto Alegre 3
Shenyang 3
Tashkent 3
Andover 2
Baotou 2
Barueri 2
Bishkek 2
Buenos Aires 2
Caxias do Sul 2
Chennai 2
Chongqing 2
Criciúma 2
Hangzhou 2
Itajubá 2
Jequié 2
Jiaxing 2
Jinhua 2
João Monlevade 2
Lomas de Zamora 2
Milan 2
Mogi das Cruzes 2
Moreno 2
Muscat 2
Nuremberg 2
Osasco 2
Pindamonhangaba 2
Ponta Grossa 2
Quito 2
Recife 2
Ribeirão das Neves 2
Riyadh 2
Saint Petersburg 2
Salvador 2
San Francisco 2
Santa Cruz do Sul 2
Santo André 2
Serra 2
São Bernardo do Campo 2
São José dos Pinhais 2
Toledo 2
Uberlândia 2
Totale 6.367
Salva come PNG Salva come JPEG
Nome #
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 244
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 194
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 141
Taxane-induced nail changes: incidence, clinical presentation and outcome 134
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 131
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 114
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 108
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 107
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 107
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 105
Determinants of sensitivity and resistance to fluoropyrimidines 104
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 104
Chemotherapy: which drug and when? 103
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 103
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 103
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 102
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 101
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 101
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 99
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 99
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 99
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 99
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 98
Current controversies in the adjuvant therapy of colon cancer 97
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 97
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 96
Bevacizumab plus fluorouracil: the value of being part of a developing story 95
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 95
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 95
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 93
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 93
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 92
The potential role of Tomudex in the treatment of advanced colorectal cancer 91
Irinotecan in combination with new agents 91
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 91
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 90
Highlights from the 2008 Gastrointestinal Cancers Symposium 90
Fatigue: a main component of anemia symptomatology 90
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 89
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 89
How uniform are postgraduate training programs in medical oncology in the European Union? 88
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 88
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 88
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 88
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 87
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 87
Urgent need for a new staging system in advanced colorectal cancer 86
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 85
Tamoxifen-induced total alopecia 85
Current strategies to reduce cisplatin toxicity 84
Role of oxaliplatin in the treatment of colorectal neoplasms 84
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 84
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 84
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 84
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 82
Optimal treatment of metastatic colorectal cancer 82
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 80
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 80
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 79
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 79
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 79
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 78
Current issues in adjuvant treatment of stage II colon cancer 77
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 77
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 76
The medical treatment of advanced colorectal 76
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 75
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 74
Improved therapeutic index of cisplatin with procaine HCl 73
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 72
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 71
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 70
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies 70
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 68
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 64
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 62
Clinical aspects of drug resistance 61
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 60
Adjuvant treatment of colorectal cancer in the elderly 59
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 59
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 59
Biochemical determinants of antineoplastic activity of fluoropyrimidines 59
The clinical management of early and advanced colorectal cancer 58
New directions in the treatment of colorectal cancer: a look to the future 57
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 57
LE ANEMIE 55
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 55
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 54
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 53
Drug resistant cells as targets for new therapies 53
THE ROLE OF METHOTREXATE IN THE TREATMENT OF GESTIONAL TROPHOBLASTIC NEOPLASM 53
Methotrexate resistant cells as target for selective chemotherapy 52
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 52
Randomized comparison of. weekly bolus five-fluorouracil with or without leucovorin in metastatic colorectal carcinoma 50
Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case 50
Effects of high dose methotrexate and leucovorin on murine haemopoietic stem cells 48
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 48
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 47
The handling of metastatic colorectal cancer 47
Last news from ASCO 2000 in the topic of colorectal cancer 46
Totale 8.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.100
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.100
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020174 0 0 0 0 0 0 0 0 0 0 0 174
2020/20211.509 25 185 33 204 42 185 71 207 293 45 173 46
2021/2022868 28 109 14 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024162 29 8 3 3 16 24 1 11 43 0 0 24
2024/20252.417 38 154 207 71 31 63 89 83 180 297 507 697
Totale 9.824